Search
Cytosorbents Corp
CTSOAdd to Watchlist
0.498USD
-0.044-8.16%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
31.25MMarket Cap
LossP/E TTM
More Details of Cytosorbents Corp Company
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Cytosorbents Corp Info
Ticker SymbolCTSO
Company nameCytosorbents Corp
IPO dateJun 17, 2005
CEOChan (Phillip P)
Number of employees149
Security typeOrdinary Share
Fiscal year-endJun 17
Address305 College Road East
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone19733298885
Websitehttps://cytosorbents.com/
Ticker SymbolCTSO
IPO dateJun 17, 2005
CEOChan (Phillip P)
Company Executives of Cytosorbents Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Phillip P. Chan, M.D., Ph.D.
Dr. Phillip P. Chan, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.04M
-13.29%
Mr. Vincent J. Capponi
Mr. Vincent J. Capponi
President, Chief Operating Officer
President, Chief Operating Officer
364.83K
-203.15%
Mr. Peter J. (Pete) Mariani, CPA
Mr. Peter J. (Pete) Mariani, CPA
Chief Financial Officer
Chief Financial Officer
116.61K
-61.31%
Mr. Alan D. Sobel, CPA
Mr. Alan D. Sobel, CPA
Independent Director
Independent Director
78.46K
--
Ms. Jiny Kim
Ms. Jiny Kim
Independent Director
Independent Director
8.52K
--
Dr. Edward R. Jones, M.D.
Dr. Edward R. Jones, M.D.
Independent Director
Independent Director
--
--
Mr. Michael G. Bator
Mr. Michael G. Bator
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Efthymios N. Deliargyris, M.D.
Dr. Efthymios N. Deliargyris, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Phillip P. Chan, M.D., Ph.D.
Dr. Phillip P. Chan, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.04M
-13.29%
Mr. Vincent J. Capponi
Mr. Vincent J. Capponi
President, Chief Operating Officer
President, Chief Operating Officer
364.83K
-203.15%
Mr. Peter J. (Pete) Mariani, CPA
Mr. Peter J. (Pete) Mariani, CPA
Chief Financial Officer
Chief Financial Officer
116.61K
-61.31%
Mr. Alan D. Sobel, CPA
Mr. Alan D. Sobel, CPA
Independent Director
Independent Director
78.46K
--
Ms. Jiny Kim
Ms. Jiny Kim
Independent Director
Independent Director
8.52K
--
Dr. Edward R. Jones, M.D.
Dr. Edward R. Jones, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
All Other
25.06M
67.62%
Germany
11.75M
31.71%
United States
249.00K
0.67%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Avenir Corporation
8.34%
Rokk LLC
7.31%
Satterfield (Thomas A Jr)
4.60%
Vanguard Capital Management, LLC
3.00%
Skylands Capital, LLC
2.72%
Other
74.02%
Shareholders
Shareholders
Proportion
Avenir Corporation
8.34%
Rokk LLC
7.31%
Satterfield (Thomas A Jr)
4.60%
Vanguard Capital Management, LLC
3.00%
Skylands Capital, LLC
2.72%
Other
74.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.06%
Individual Investor
7.56%
Corporation
7.31%
Investment Advisor/Hedge Fund
4.36%
Hedge Fund
3.14%
Family Office
0.80%
Research Firm
0.18%
Bank and Trust
0.06%
Venture Capital
0.05%
Other
58.48%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
97
16.20M
25.84%
-1.03M
2025Q4
98
16.29M
29.02%
--
2025Q3
105
16.36M
29.12%
-250.79K
2025Q2
114
16.81M
30.05%
-683.16K
2025Q1
120
17.53M
28.41%
-230.06K
2024Q4
120
16.37M
34.77%
-1.42M
2024Q3
120
17.79M
36.10%
-511.38K
2024Q2
137
18.34M
39.80%
-1.26M
2024Q1
170
19.60M
43.42%
-3.07M
2023Q4
184
20.73M
36.88%
+3.89M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Avenir Corporation
5.23M
8.34%
+147.26K
+2.90%
Dec 31, 2025
Rokk LLC
4.02M
6.41%
--
--
Apr 17, 2025
Satterfield (Thomas A Jr)
2.89M
4.6%
+2.89M
--
Jan 13, 2025
Skylands Capital, LLC
1.85M
2.96%
-272.75K
-12.82%
Dec 31, 2025
Neuberger Berman, LLC
1.63M
2.59%
+27.64K
+1.73%
Dec 31, 2025
CM Management, LLC
1.48M
2.35%
+188.37K
+14.62%
Dec 31, 2025
Chan (Phillip P)
1.17M
1.87%
+100.00K
+9.31%
Nov 18, 2025
BlackRock Institutional Trust Company, N.A.
759.29K
1.21%
+5.74K
+0.76%
Dec 31, 2025
Geode Capital Management, L.L.C.
603.77K
0.96%
+2.32K
+0.39%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
